keyword
MENU ▼
Read by QxMD icon Read
search

HFREF

keyword
https://www.readbyqxmd.com/read/28638961/evaluation-of-systolic-and-diastolic-properties-of-hypertensive-heart-failure-using-speckle-tracking-echocardiography-with-high-volume-rates
#1
Shingo Minatoguchi, Masanori Kawasaki, Ryuhei Tanaka, Takashi Yoshizane, Koji Ono, Maki Saeki, Maki Nagaya, Hidemaro Sato, Kazuhiko Nishigaki, Toshiyuki Noda, Michael R Zile, Shinya Minatoguchi
Left ventricular (LV) properties in hypertension (HTN) could be deteriorated by pressure overload, especially in endocardium, resulting in hypertensive heart failure (HHF). We sought to noninvasively examine LV systolic and diastolic functions at three myocardial layers in HTN and elucidate features of HHF by speckle-tracking echocardiography (STE) with high volume rates. We examined normotensive controls (n = 54), HTN patients without LV hypertrophy (LVH) (n = 50), and HTN patients with LVH (n = 40) and HHF patients (n = 45)...
June 21, 2017: Heart and Vessels
https://www.readbyqxmd.com/read/28629552/comparative-analysis-of-four-scores-to-stratify-patients-with-heart-failure-and-reduced-ejection-fraction
#2
Pedro Freitas, Carlos Aguiar, António Ferreira, António Tralhão, António Ventosa, Miguel Mendes
There are several prognostic risk scores available for patients with heart failure with reduced ejection fraction (HFrEF) that can aid in the decision of listing candidates for heart transplant (HTx). A direct comparison between these scores has not been performed. Therefore, our objective was to evaluate the calibration and discriminative power of 4 contemporary HF scores. A retrospective analysis of 259 patients with HFrEF who underwent cardiopulmonary exercise test was conducted. The Heart Failure Survival Score (HFSS), Seattle Heart Failure Model (SHFM), Meta-analysis Global Group in Chronic Heart Failure (MAGGIC), and Metabolic Exercise Cardiac Kidney Index (MECKI) were compared...
May 11, 2017: American Journal of Cardiology
https://www.readbyqxmd.com/read/28627045/heart-rate-and-its-reduction-in-chronic-heart-failure-and-beyond
#3
REVIEW
Aleksandra Nikolovska Vukadinović, Davor Vukadinović, Jeffrey Borer, Martin Cowie, Michel Komajda, Mitja Lainscak, Karl Swedberg, Michael Böhm
Heart rate (HR) is associated with cardiovascular outcomes in all the stages of the cardiovascular continuum as well as in patients with pulmonary, cerebrovascular, and renal disease, sepsis, cancer, and erectile dysfunction. In patients with cardiovascular disease, but also in the general population, increased HR represents an important indicator of mortality with each acceleration of HR over 70 b.p.m. increasing the risk. In patients in sinus rhythm with chronic heart failure with reduced ejection fraction (HFrEF), a HR >70 b...
June 19, 2017: European Journal of Heart Failure
https://www.readbyqxmd.com/read/28625374/change-the-management-of-patients-with-heart-failure-rationale-and-design-of-the-champ-hf-registry
#4
Adam D DeVore, Laine Thomas, Nancy M Albert, Javed Butler, Adrian F Hernandez, J Herbert Patterson, John A Spertus, Fredonia B Williams, Stuart J Turner, Wing W Chan, Carol I Duffy, Kevin McCague, Xiaojuan Mi, Gregg C Fonarow
Heart failure (HF) with reduced ejection fraction (HFrEF) is a common and costly condition that diminishes patients' health status and confers a poor prognosis. Despite the availability of multiple guideline-recommended pharmacologic and cardiac device therapies for patients with chronic HFrEF, outcomes remain suboptimal. Currently, there is limited insight into the rationale underlying clinical decisions by health care providers and patient factors that guide the use and intensity of outpatient HF treatments...
July 2017: American Heart Journal
https://www.readbyqxmd.com/read/28624484/progression-to-stage-d-heart-failure-among-outpatients-with-stage-c-heart-failure-and-reduced-ejection-fraction
#5
Andreas P Kalogeropoulos, Ayman Samman-Tahhan, Jeffrey S Hedley, Andrew A McCue, Jonathan B Bjork, David W Markham, Kunal N Bhatt, Vasiliki V Georgiopoulou, Andrew L Smith, Javed Butler
OBJECTIVES: This study sought to estimate the rate of progression to Stage D heart failure (HF) among outpatients with Stage C HF and to identify risk factors for progression. BACKGROUND: The pool of patients who may be candidates for advanced HF therapies is growing. METHODS: We estimated 3-year progression to clinically determined Stage D HF and competing mortality among 964 outpatients with Stage C heart failure with reduced ejection fraction (HFrEF), where ejection fraction is ≤40%...
June 14, 2017: JACC. Heart Failure
https://www.readbyqxmd.com/read/28624483/biomarker-profiles-of-acute%C3%A2-heart%C3%A2-failure%C3%A2-patients-with-a%C3%A2-mid-range-ejection%C3%A2-fraction
#6
Jasper Tromp, Mohsin A F Khan, Robert J Mentz, Christopher M O'Connor, Marco Metra, Howard C Dittrich, Piotr Ponikowski, John R Teerlink, Gad Cotter, Beth Davison, John G F Cleland, Michael M Givertz, Daniel M Bloomfield, Dirk J van Veldhuisen, Hans L Hillege, Adriaan A Voors, Peter van der Meer
OBJECTIVES: In this study, the authors used biomarker profiles to characterize differences between patients with acute heart failure with a midrange ejection fraction (HFmrEF) and compare them with patients with a reduced (heart failure with a reduced ejection fraction [HFrEF]) and preserved (heart failure with a preserved ejection fraction [HFpEF]) ejection fraction. BACKGROUND: Limited data are available on biomarker profiles in acute HFmrEF. METHODS: A panel of 37 biomarkers from different pathophysiological domains (e...
May 31, 2017: JACC. Heart Failure
https://www.readbyqxmd.com/read/28620053/exercise-training-improve-cardiac-autonomic-control-cardiac-function-and-arrhythmogenesis-in-rats-with-preserved-ejection-fraction-heart-failure
#7
David C Andrade, Alexis Arce-Alvarez, Camilo Toledo, Hugo S Diaz, Claudia Lucero, Harold D Schultz, Noah J Marcus, Rodrigo Del Rio
Chronic heart failure is characterized by autonomic imbalance, cardiac dysfunction and arrhythmogenesis. It has been shown that exercise training (ExT) improves central nervous system oxidative stress, autonomic control and cardiac function in heart failure with reduced ejection fraction (HFrEF), however to date no comprehensive studies have addressed the effects of ExT, if any, on oxidative stress in brainstem cardiovascular areas, cardiac autonomic balance, arrhythmogenesis and cardiac function in heart failure with preserved ejection fraction (HFpEF)...
June 15, 2017: Journal of Applied Physiology
https://www.readbyqxmd.com/read/28615366/significance-of-ischemic-heart-disease-in-patients-with-heart-failure-and-preserved-midrange-and-reduced-ejection-fraction-a-nationwide-cohort-study
#8
Ola Vedin, Carolyn S P Lam, Angela S Koh, Lina Benson, Tiew Hwa Katherine Teng, Wan Ting Tay, Oscar Ö Braun, Gianluigi Savarese, Ulf Dahlström, Lars H Lund
BACKGROUND: The pathogenic role of ischemic heart disease (IHD) in heart failure (HF) with reduced ejection fraction (HFrEF; EF <40%) is well established, but its pathogenic and prognostic significance in HF with midrange (HFmrEF; EF 40%-50%) and preserved EF (HFpEF; EF ≥50%) has been much less explored. METHODS AND RESULTS: We evaluated 42 987 patients from the Swedish Heart Failure Registry with respect to baseline IHD, outcomes (IHD, HF, cardiovascular events, and all-cause death), and EF change during a median follow-up of 2...
June 2017: Circulation. Heart Failure
https://www.readbyqxmd.com/read/28611096/thymosin-beta-4-is-elevated-in-women-with-heart-failure-with-preserved-ejection-fraction
#9
Chester L Drum, Warren K Y Tan, Siew-Pang Chan, Leroy S Pakkiri, Jenny P C Chong, Oi-Wah Liew, Tze-Pin Ng, Lieng-Hsi Ling, David Sim, Kui-Toh G Leong, Daniel P S Yeo, Hean-Yee Ong, Fazlur Jaufeerally, Raymond C C Wong, Ping Chai, Adrian F Low, Pia Davidsson, Mathias Liljeblad, Ann-Sofi Söderling, Li-Ming Gan, Ratan V Bhat, Kristy Purnamawati, Carolyn S P Lam, A Mark Richards
BACKGROUND: Thymosin beta-4 (TB4) is an X-linked gene product with cardioprotective properties. Little is known about plasma concentration of TB4 in heart failure (HF), and its relationship with other cardiovascular biomarkers. We sought to evaluate circulating TB4 in HF patients with preserved (HFpEF) or reduced (HFrEF) ejection fraction compared to non-HF controls. METHODS AND RESULTS: TB4 was measured using a liquid chromatography and mass spectrometry assay in age- and sex-matched HFpEF (n=219), HFrEF (n=219) patients, and controls (n=219) from a prospective nationwide study...
June 13, 2017: Journal of the American Heart Association
https://www.readbyqxmd.com/read/28610685/the-overweight-paradox-in-the-prognosis-of-acute-coronary-syndrome-for-patients-with-heart-failure-a-truth-for-all-a-10-year-follow-up-study
#10
Matina Kouvari, Christina Chrysohoou, Eleptherios Tsiamis, Hara Kosyfa, Lemonia Kalogirou, Androniki Filippou, Stelios Iosifidis, Panagiotis Aggelopoulos, Christos Pitsavos, Dimitris Tousoulis
OBJECTIVES: In established acute coronary syndrome (ACS) with major complications (i.e. heart failure), overweight/obese patients usually have a survival advantage. To what extent this is irrespective of other characteristics remains inconclusive. The role of body mass index (BMI) in ACS prognosis (fatal/recurrent non-fatal cardiac episodes) and background potential interactions were evaluated. STUDY DESIGN: In 2006-2009, 1000 consecutive patients, hospitalized at First Cardiology Clinic of Athens with a diagnosis of ACS were enrolled in the study...
August 2017: Maturitas
https://www.readbyqxmd.com/read/28606099/pulmonary-hemodynamics-and-effects-of-phosphodiesterase-type-5-inhibition-in-heart-failure-a-meta-analysis-of-randomized-trials
#11
In-Chang Hwang, Yong-Jin Kim, Jun-Bean Park, Yeonyee E Yoon, Seung-Pyo Lee, Hyung-Kwan Kim, Goo-Yeong Cho, Dae-Won Sohn
BACKGROUND: Previous studies suggested that phosphodiesterase 5 inhibitors (PDE5i) have a beneficial effect in patients with heart failure (HF), although the results were inconsistent. We performed a meta-analysis to evaluate the effect of PDE5i in HF patients, and investigated the relationship between PDE5i effects and pulmonary hemodynamics. METHOD: We searched PubMed, EMBASE and the Cochrane Library for randomized controlled trials (RCTs) that compared PDE5i with placebo in HF with reduced ejection fraction (HFrEF) or HF with preserved EF (HFpEF)...
June 12, 2017: BMC Cardiovascular Disorders
https://www.readbyqxmd.com/read/28602370/the-role-of-positive-inotropic-drugs-in-the-treatment-of-older-adults-with-heart-failure-and-reduced-ejection-fraction
#12
REVIEW
Daniel J Dooley, Phillip H Lam, Ali Ahmed, Wilbert S Aronow
Positive inotropic drugs have long been studied for their potential benefits in patients with heart failure and reduced ejection fraction (HFrEF). Although there has been an extensive amount of research about the clinical effects of these drugs in general, few studies examined their effect in older patients. Therefore, there is little or no evidence to guide the use of positive inotropes in older patients with HFrEF. However, recommendations from national heart failure guidelines may be generalized to older HFrEF patients on an individual basis, taking into consideration the basic geriatric principles of pharmacotherapy: start low and go slow...
July 2017: Heart Failure Clinics
https://www.readbyqxmd.com/read/28602367/heart-failure-with-preserved-ejection-fraction-in-older-adults
#13
REVIEW
Bharathi Upadhya, Dalane W Kitzman
Most elderly patients, particularly women, who have heart failure, have a preserved ejection fraction. Patients with this syndrome have severe symptoms of exercise intolerance, frequent hospitalizations, and increased mortality. Despite the importance of heart failure with preserved ejection fraction (HFpEF), the understanding of its pathophysiology is incomplete, and optimal treatment remains largely undefined. Unlike the management of HFrEF, there is a paucity of large evidence-based trials demonstrating morbidity and mortality benefit for the treatment of HFpEF...
July 2017: Heart Failure Clinics
https://www.readbyqxmd.com/read/28601914/left-ventricular-ejection-fraction-as-therapeutic-target-is-it-the-ideal-marker
#14
REVIEW
V Katsi, G Georgiopoulos, A Laina, E Koutli, J Parissis, C Tsioufis, P Nihoyannopoulos, D Tousoulis
Heart failure (HF) consists the fastest growing clinical cardiac disease. HF patients are categorized on the basis of underlying left ventricular ejection fraction (LVEF) into HF with preserved EF (HFpEF), reduced LVEF (HFrEF), and mid-range LVEF (HFmrEF). While LVEF is the most commonly used surrogate marker of left ventricular (LV) systolic function, the implementation of two-dimensional echocardiography in estimating this parameter imposes certain caveats on current HF classification. Most importantly, LVEF could fluctuate in repeated measurements or even recover after treatment, thus blunting the borders between proposed categories of HF and enabling upward classification of patients...
June 10, 2017: Heart Failure Reviews
https://www.readbyqxmd.com/read/28599060/evaluation-of-pharmacokinetic-and-pharmacodynamic-drug-drug-interaction-of-sacubitril-valsartan-lcz696-and-sildenafil-in-patients-with-mild-to-moderate-hypertension
#15
Hsiu-Ling Hsiao, Thomas H Langenickel, Jesika Petruck, Kiran Kode, Surya Ayalasomayajula, Uwe Schuehly, Michael Greeley, Parasar Pal, Wei Zhou, Margaret F Prescott, Gangadhar Sunkara, Iris Rajman
Sacubitril/valsartan (LCZ696) is indicated for the treatment of patients with heart failure and reduced ejection fraction (HFrEF). Since patients with HFrEF may receive sacubitril/valsartan and sildenafil, both increasing cGMP, the present study evaluated the pharmacokinetic and pharmacodynamic drug interaction potential between sacubitril/valsartan and sildenafil. In this open-label, 3-period, single sequence study, patients with mild-to-moderate hypertension (153.8±8.2 mm Hg mean SBP) received a single dose of sildenafil 50 mg, sacubitril/valsartan 400 mg once daily for 5 days, and sacubitril/valsartan and sildenafil co-administration...
June 9, 2017: Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28597497/right-ventricular-dysfunction-in-left-sided-heart-failure-with-preserved-versus-reduced-ejection-fraction
#16
Lena Bosch, Carolyn S P Lam, Lingli Gong, Siew Pang Chan, David Sim, Daniel Yeo, Fazlur Jaufeerally, Kui Toh Gerard Leong, Hean Yee Ong, Tze Pin Ng, Arthur Mark Richards, Fatih Arslan, Lieng H Ling
BACKGROUND: Right ventricular (RV) dysfunction is recognized as a major prognostic factor in left-sided heart failure (HF). However, the relative contribution of RV dysfunction in HF with preserved (HFpEF) vs. reduced ejection fraction (HFrEF) is unclear. METHODS AND RESULTS: Right ventricular longitudinal strain (RVLS), tricuspid annular plane systolic excursion (TAPSE) and pulmonary artery systolic pressure (PASP) were determined by echocardiography in 657 age- and gender-matched groups of patients with HFpEF [left ventricular ejection fraction (LVEF) ≥50%; n=219] and HFrEF (LVEF <50%; n=219) and in controls without HF (n=219) from an Asian population-based cohort study...
June 8, 2017: European Journal of Heart Failure
https://www.readbyqxmd.com/read/28585906/elevation-of-plasma-oncostatin-m-in-heart-failure
#17
Damien Gruson, Benjamin Ferracin, Sylvie A Ahn, Michel F Rousseau
AIM: Oncostatin M (OSM) is an inflammatory cytokine of the gp130 family. OSM could participate in adverse cardiovascular remodeling through regulation of FGF23. MATERIALS & METHODS: OSM levels were determined in 80 heart failure patients with reduced left ventricular ejection fraction (HFrEF). RESULTS: OSM levels are significantly increased in HFrEF patients compared with healthy subjects. We have also demonstrated that, in HFrEF patients, plasma OSM levels are correlated to parathyroid hormone PTH(1-84) and 1,25(OH)2D, two other biomarkers related to bone and mineral metabolism and associated to adverse cardiovascular outcomes...
June 6, 2017: Future Cardiology
https://www.readbyqxmd.com/read/28580625/mineralocorticoid-receptor-antagonist-pattern-of-use-in-heart-failure-with-reduced-ejection-fraction-findings-from-biostat-chf
#18
João Pedro Ferreira, Patrick Rossignol, Jean-Loup Machu, Abhinav Sharma, Nicolas Girerd, Stefan D Anker, John G Cleland, Kenneth Dickstein, Gerasimos Filippatos, Hans L Hillege, Chim C Lang, Jozine Ter Maaten, Marco Metra, Leong Ng, Piotr Ponikowski, Nilesh J Samani, Dirk J van Veldhuisen, Aeilko H Zwinderman, Adriaan Voors, Faiez Zannad
AIMS: Mineralocorticoid receptor antagonists (MRAs) are recommended (unless contraindicated) to all patients with heart failure with reduced ejection fraction (HFrEF). However, MRAs are still largely underused in routine clinical practice. This study aims to describe the determinants and pattern of use of MRAs in HFrEF. METHODS AND RESULTS: BIOSTAT-CHF is a European multicentre, prospective study which enrolled patients suboptimally treated with angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEi/ARBs) and/or beta-blockers, with the aim of optimizing guideline-based use of these agents...
June 5, 2017: European Journal of Heart Failure
https://www.readbyqxmd.com/read/28579160/complex-energy-metabolic-changes-in-heart-failure-with-preserved-ejection-fraction-and-heart-failure-with-reduced-ejection-fraction
#19
REVIEW
Kirstie A De Jong, Gary D Lopaschuk
Alterations in cardiac energy metabolism contribute to the severity of heart failure. However, the energy metabolic changes that occur in heart failure are complex, and are dependent not only on the severity and type of heart failure present, but also on the coexistence of common comorbidities such as obesity and type 2 diabetes. In this article we review the cardiac energy metabolic changes that occur in heart failure. An emphasis is made on distinguishing the differences in cardiac energy metabolism between heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF) and in clarifying the common misconceptions surrounding the fate of fatty acids and glucose in the failing heart...
March 19, 2017: Canadian Journal of Cardiology
https://www.readbyqxmd.com/read/28579091/characteristics-and-outcomes-of-heart-failure-hospitalization-before-implementation-of-a-heart-failure-clinic-the-precic-study
#20
Irene Marques, Sara Abreu, Manuela V Bertão, Betânia Ferreira, Raquel Lopes Ramos, Juliana Lopes, Sandra Nunes, Denisa Mendonça, Laetitia Teixeira
OBJECTIVE: This study aims to characterize patients hospitalized for acute heart failure (HF) in an internal medicine department and their one-year mortality and rate of rehospitalization for decompensated HF. METHODS: This retrospective observational study enrolled all patients discharged in 2012 after hospitalization for acute HF. Discharge summaries, clinical records and telephone interviews were analysed. The data reports to the year before implementation of a heart failure clinic...
May 31, 2017: Portuguese Journal of Cardiology: An Official Journal of the Portuguese Society of Cardiology
keyword
keyword
71067
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"